Navigation Links
A Window Into Parkinson's Disease
Date:11/12/2008

NEW YORK, Nov. 12 /PRNewswire-USNewswire/ -- A new study being published in this Friday's online edition of Cell will help answer the question, what causes Parkinson's disease?

One of the most pressing questions in the medical research into Parkinson's disease is what causes the sensitive cells in the brain to die in the first place. Answering this question has been especially difficult because there are two nearly identical types of brain cells that produce dopamine and they are mixed together in the same brain regions. However, only one cell type is affected in Parkinson's, the other is spared. Scientists have wanted to compare these closely related brain cells in the hope that differences between the two would explain why the sensitive cells die. This understanding will suggest opportunities for intervention.

The main obstacle has been the infeasibility of separating the two cell types for analysis. Doctors Paul Greengard and Myriam Heiman of The Michael Stern Parkinson's Disease Foundation and their colleagues at The Rockefeller University have developed a system that solves this fundamental technological problem. These scientists have focused on discovering which genes are turned on or off in the two similar cell types. If one views a cell as a computer, then the genes can be viewed as software. Unique programs operate depending on which genes are turned on. When genes are "turned on", they cause the cell to produce specific proteins.

What makes cells vulnerable to Parkinson's disease depends largely on the kinds and amounts of proteins they produce, or their "translational profile."

The new method discovered by Greengard, Heiman, and colleagues, Translating Ribosome Affinity Purification (TRAP), reveals translational profiles in cells by isolating the genetic messages as they pass through the protein production factories called ribosomes.

This new technique will help propel the scientific community, which has struggled to sleuth out the subtle molecular differences amongst the hundreds of specialized cell types that are tangled together in the brain tissues, toward a better understanding of the causes of Parkinson's disease.

"We can look at a thousand genes instead of one at a time, so things should clear a thousand times faster," says Greengard.

The novel TRAP tool will also help study the biochemical basis of Alzheimer's, Huntington's and other neurological diseases.

http://www.parkinsoninfo.org

About The Michael Stern Parkinson's Research Foundation

Finding the cause, developing treatments and discovering the cure for Parkinson's disease is the focus of The Michael Stern Parkinson's Research Foundation. Established in 2001 to support and expand the pioneering research of Paul Greengard, Nobel laureate, at The Rockefeller University and select academic research centers in the U.S.

Media contact:

For information on The Michael Stern Parkinson's Research Foundation, please contact Betsey Odell at 646-381-5148

For information on the scientific research, please contact Dr. William Netzer at netzerw@mail.rockefeller.edu


'/>"/>
SOURCE The Michael Stern Parkinson?s Research Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
2. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
3. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
4. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
5. Physicians Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease
6. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
7. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
8. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
9. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
10. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 One of ... has announced the formation of a new biotechnology company, Noxopharm Limited ... $6m in an IPO and to list on the ASX. ... candidate, NOX66, ready to enter a Phase 1 clinical study later ... designed to address one of the biggest problems facing cancer patients ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... , the only authorized OSHA Training Institute Education Center headquartered in Northern California, ... their workers from extreme heat at their worksites. Employers with workers exposed ...
(Date:6/27/2016)... ... , ... "FCPX editors can now reveal their media with growing colorful split ... Austin - CEO of Pixel Film Studios. , ProSlice Color brings the split ... now reveal the media of their split screens with growing colorful panels. , ProSlice ...
(Date:6/27/2016)... ... 27, 2016 , ... TherapySites, the leading website ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to ... adding exclusive benefits and promotional offers. , "TCA is extremely excited about this ...
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/27/2016)... ... 2016 , ... A revolution is underway. Brooklyn-based company, ... for the millions of people who require these medical transport services annually. ... the use of technology. Now, SmartEMS has put forth an industry-changing app that ...
Breaking Medicine News(10 mins):